Dianthus Therapeutics, Inc. $DNTH Stock Holdings Lowered by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC cut its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 1.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 73,266 shares of the company’s stock after selling 1,106 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Dianthus Therapeutics were worth $1,365,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RA Capital Management L.P. increased its stake in shares of Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after purchasing an additional 1,000,333 shares during the period. Walleye Capital LLC grew its holdings in Dianthus Therapeutics by 29.0% in the 1st quarter. Walleye Capital LLC now owns 106,931 shares of the company’s stock worth $1,940,000 after buying an additional 24,041 shares in the last quarter. Vestal Point Capital LP increased its position in Dianthus Therapeutics by 58.1% in the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock valued at $30,839,000 after acquiring an additional 625,069 shares during the period. Nuveen LLC bought a new stake in Dianthus Therapeutics during the 1st quarter valued at $1,168,000. Finally, Candriam S.C.A. acquired a new position in Dianthus Therapeutics during the 1st quarter worth $4,510,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $33.74 on Friday. Dianthus Therapeutics, Inc. has a 12 month low of $13.36 and a 12 month high of $40.16. The company has a market capitalization of $1.09 billion, a P/E ratio of -10.38 and a beta of 1.58. The company’s 50 day simple moving average is $33.36 and its 200 day simple moving average is $24.42.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.15% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Guggenheim increased their target price on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Robert W. Baird boosted their price target on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 9th. Stifel Nicolaus upped their price target on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, Truist Financial assumed coverage on shares of Dianthus Therapeutics in a report on Tuesday, October 14th. They issued a “buy” rating and a $56.00 price objective for the company. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.88.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.